- Record: found
- Abstract: found
- Article: not found
Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
Andrea Gershon
1 ,
Ruth Croxford ,
Andrew Calzavara ,
Teresa To ,
Matthew B Stanbrook ,
Ross Upshur ,
Thérèse A Stukel
Jul 8 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.